AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,770,122 | +6.6% | 803,464 | +10.1% | 1.90% | +24.5% |
| Q2 2023 | $9,167,845 | +59.0% | 729,924 | +40.4% | 1.53% | +38.0% |
| Q1 2023 | $5,766,600 | -7.0% | 519,982 | +2.4% | 1.11% | -7.7% |
| Q4 2022 | $6,198,797 | +3.7% | 507,682 | -11.4% | 1.20% | +1.9% |
| Q3 2022 | $5,979,000 | -0.7% | 572,682 | +2.1% | 1.18% | -3.0% |
| Q2 2022 | $6,024,000 | +2.0% | 560,882 | -10.1% | 1.21% | +15.7% |
| Q1 2022 | $5,907,000 | -58.9% | 623,782 | -49.8% | 1.05% | -51.4% |
| Q4 2021 | $14,355,000 | -37.6% | 1,242,882 | -48.4% | 2.16% | +12.8% |
| Q3 2021 | $23,021,000 | +14.2% | 2,410,604 | +15.3% | 1.92% | +17.4% |
| Q2 2021 | $20,161,000 | +15.5% | 2,091,404 | +18.4% | 1.63% | +23.3% |
| Q1 2021 | $17,455,000 | -50.7% | 1,766,704 | +15.1% | 1.32% | -47.0% |
| Q4 2020 | $35,434,000 | +16.5% | 1,534,604 | -28.7% | 2.50% | -4.5% |
| Q3 2020 | $30,409,000 | +15.2% | 2,153,633 | +23.0% | 2.61% | +7.8% |
| Q2 2020 | $26,404,000 | +83.4% | 1,750,913 | +12.4% | 2.42% | -12.3% |
| Q1 2020 | $14,396,000 | -28.2% | 1,557,961 | -24.4% | 2.76% | -7.7% |
| Q4 2019 | $20,064,000 | -27.3% | 2,059,961 | -40.2% | 2.99% | -37.1% |
| Q3 2019 | $27,604,000 | -33.5% | 3,441,922 | +3.5% | 4.76% | -4.0% |
| Q2 2019 | $41,491,000 | -10.1% | 3,324,623 | -2.1% | 4.96% | -10.7% |
| Q1 2019 | $46,167,000 | -4.3% | 3,394,623 | -32.6% | 5.55% | -15.3% |
| Q4 2018 | $48,251,000 | -18.0% | 5,036,590 | +3.5% | 6.56% | +5.0% |
| Q3 2018 | $58,846,000 | +2.0% | 4,867,290 | +31.8% | 6.25% | -3.1% |
| Q2 2018 | $57,695,000 | +12.6% | 3,693,690 | +8.5% | 6.45% | +14.9% |
| Q1 2018 | $51,219,000 | +24.9% | 3,405,541 | +19.5% | 5.62% | +9.6% |
| Q4 2017 | $41,023,000 | +12.7% | 2,850,769 | +18.1% | 5.13% | +9.4% |
| Q3 2017 | $36,386,000 | +3.7% | 2,412,870 | -30.7% | 4.69% | +22.2% |
| Q2 2017 | $35,084,000 | +14.1% | 3,483,990 | -19.2% | 3.84% | +6.9% |
| Q1 2017 | $30,742,000 | +21.3% | 4,311,696 | -15.5% | 3.59% | +27.8% |
| Q4 2016 | $25,348,000 | -18.3% | 5,100,198 | +21.6% | 2.81% | -7.8% |
| Q3 2016 | $31,039,000 | +18.7% | 4,194,452 | -12.4% | 3.05% | +12.9% |
| Q2 2016 | $26,147,000 | -66.5% | 4,788,738 | -48.1% | 2.70% | -28.4% |
| Q1 2016 | $77,961,000 | +0.8% | 9,226,145 | +15.7% | 3.77% | +14.3% |
| Q4 2015 | $77,342,000 | -9.5% | 7,973,436 | +30.5% | 3.30% | -15.8% |
| Q3 2015 | $85,496,000 | +20.7% | 6,111,227 | +22.1% | 3.92% | +32.6% |
| Q2 2015 | $70,811,000 | +30.5% | 5,004,322 | +0.4% | 2.95% | +43.4% |
| Q1 2015 | $54,249,000 | +36.8% | 4,986,138 | +4.6% | 2.06% | +15.9% |
| Q4 2014 | $39,649,000 | +3231.8% | 4,765,498 | +2282.7% | 1.78% | +3456.0% |
| Q3 2014 | $1,190,000 | – | 200,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |